Table 2.
EORTC QLQ-C30: between-group analysis at 2 months after the beginning of the exercise (end of treatment) (T1).
| EORTC QLQ-C30 | T1 Group IG | T1 Group CG | p-Value |
|---|---|---|---|
| QL2 | 70.9 (25.0–100.0) | 62.5 (41.7–66.7) | 0.330 |
| PF2 | 96.5 (86.7–100.0) | 83.4 (60.0–87.0) | 0.030 * |
| RF2 | 92.0 (50.0–100.0) | 83.3 (83.0–84.0.) | 0.228 |
| EF | 87.5 (58.0–100.0) | 75.0 (58.3–75.0) | 0.249 |
| CF | 100.0 (100.0–100.0) | 74.8 (66.6–100.0) | 0.018 * |
| SF | 68.5 (50.0–100.0) | 83.3 (50.0–100.0) | 0.912 |
| FA | 22.8 (0.0–33.3) | 55.6 (33.3–66.7) | 0.017 * |
| NV | 0.0 (0.0–16.6) | 0.0 (0.0–0.0) | 0.414 |
| PA | 0.0 (0.0–33.3) | 8.4 (0.0–16.7) | 0.807 |
| DY | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1000 |
| SL | 16.7 (0.0–66.7) | 50.0 (0.0–66.7) | 0.309 |
| AP | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.759 |
| CO | 0.0 (0.0–66.7) | 16.7 (0.0–33.3) | 0.429 |
| DI | 0.0 (0.0–33.3) | 0.0 (0.0–33.3) | 0.789 |
| FI | 0.0 (0.0–0.0) | 0.0 (0.0–33.3) | 0.221 |
Abbreviations: IG, Intervention Group; CG, Control Group; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire; QL, Global Health Status/Quality of Life; PF, Physical Functioning; RF, Role Functioning; EF, Emotional Functioning; CF, Cognitive Functioning; SF, Social Functioning; FA, Fatigue; NV, Nausea and Vomiting; PA, Pain; DY, Dyspnea; SL, Insomnia; AP, Appetite Loss; CO, Constipation; DI, Diarrhea; FI, Financial Difficulties. * p-value < 0.05.